logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Ikena Oncology, Inc.


USPTO Granted Patents = 16


Trademarks = 2

Forward Citations = 21

Loading Chart...
Loading Chart...

19 inventors (with patents filed for the assignee):

goldMedal Alfredo C Castro (15 out of 114 patents)

silverMedal Catherine Anne Evans (5 out of 44 patents)

bronzeMedal Michael J Burke (4 out of 5 patents)

4.  Sabine K Ruppel (2 out of 14 patents)

5.  Karen J McGovern (2 out of 11 patents)

6.  James Martin Nolan, Iii (2 out of 2 patents)

7.  Sarah Jean Bethune (2 out of 2 patents)

8.  Corinne Marie Folberth (2 out of 2 patents)

9.  Thomas A Wynn (2 out of 2 patents)

10.  Eric Haines (2 out of 2 patents)

11.  Sergio L Santillana Soto (2 out of 2 patents)

12.  Lan Xu (2 out of 3 patents)

13.  Oksana Zavidij (2 out of 2 patents)

14.  Everett Stone (1 out of 35 patents)

15.  George Georgiou (1 out of 76 patents)


16 patents:

1. 12692485 - PEGYLATED KYNURENINASE ENZYMES AND USES THEREOF FOR THE TREATMENT OF CANCER (2026-07-28),
2. 12459895 - MEK inhibitors and uses thereof (2025-11-04),
3. 12162884 - Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a] [1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine as aryl hydrocarbon receptor (AHR) inhibitors (2024-12-10),
4. 12077542 - Indole AHR inhibitors and uses thereof (2024-09-03),
5. 12030876 - Aryl hydrocarbon receptor (AHR) agonists and uses thereof (2024-07-09),
6. 11925651 - TEAD inhibitors and uses thereof (2024-03-12),
7. 11878958 - MEK inhibitors and uses thereof (2024-01-23),
8. 11760728 - Tead inhibitors and uses thereof (2023-09-19),
9. 11608329 - Aryl hydrocarbon receptor (AHR) agonists and uses thereof (2023-03-21),
10. 11591339 - Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors (2023-02-28),
11. 11555026 - AHR inhibitors and uses thereof (2023-01-17),
12. 11458149 - TEAD inhibitors and uses thereof (2022-10-04),
13. 11358969 - Indole AHR inhibitors and uses thereof (2022-06-14),
14. 11274082 - Tead inhibitors and uses thereof (2022-03-15),
15. 10696650 - AHR inhibitors and uses thereof (2020-06-30),
Company Overview
Ikena Oncology, Inc. is a biotechnology company based in Boston, MA, focused on developing innovative therapies for cancer treatment. The company specializes in precision medicine, leveraging its expertise in genetic and molecular biology to create targeted therapies that address specific cancer pathways. Ikena's research is centered on understanding the complexities of tumor biology, aiming to improve patient outcomes through personalized treatment approaches. Its commitment to advancing oncology therapeutics positions it as a key player in the fight against cancer.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Ikena Oncology, Inc. USPTO Patent Assignee Logo
16 Patents

#135 in Boston, MA

#1,203 in Massachusetts

#19,935 in US

#37,868 in the World

Boston, MA (US)
Boston, MA, United States of America

Ikena Oncology, Inc.

Forward Citations = 21

19 inventors:

goldMedal Alfredo C Castro (15 out of 114 patents)

silverMedal Catherine Anne Evans (5 out of 44 patents)

bronzeMedal Michael J Burke (4 out of 5 patents)

4.  Sabine K Ruppel (2 out of 14 patents)

5.  Karen J McGovern (2 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ikena Oncology, Inc.. Retrieved from https://idiyas.com/company/ikena-oncology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…